Acceleron Pharma 10K 2020 Annual report | XLRN Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abide, accessibility, ACR, Actemra, Adam, agonist, AHA, Aid, air, alongside, alpha, anytime, area, arrest, assembly, auto, autoimmune, autoimmunity, autotemcel, azathioprine, Backstrom, belumosudil, Bermuda, beta, betibeglogene, Biden, brand, Breaking, Bristol, broader, byReferenceherein, cardiac, carryback, catheterization, CBER, cedazuridine, CEO, chain, champion, Chemomab, circulatory, clarified, CMML, commitment, committed, concordance, condensed, conferencing, configured, confirmatory, contact, convened, core, cough, coupling, CRO, culture, Cumberland, curb, cyclophosphamide, decitabine, dialogue, donut, dysregulation, embody, Emerald, endeavor, environment, Esbriet, Esq, exacerbated, ExhibitNumber, Fc, FCPA, fellow, Fibrocell, Filedwith, flow, footprint, forthcoming, fostering, fromForm, gap, Genentech, geography, Gossamer, hamill, harassment, hard, heightened, hemodynamic, highest, highlighted, hole, home, Horizon, hormone, HVAC, HYPERION, hypokalemia, ifetroban, ILD, immune, imperative, inconvenient, Inqovi, Insider, instability, insult, internationally, interstitial, inventor, Invited, IP, irreversible, Jay, Kadmon, laura, leave, leaving, lenabasum, lessen, leverage, Likewise, lot, LS, lung, mmHg, mobility, mofetil, mono, mPAP, mRSS, MSA, multifaceted, mycophenolate, myelomonocytic, nausea, NDA, neoplasm, nintedanib, nominal, nominee, nonrenewal, OFEV, online, onsite, Onureg, opposed, opposite, opted, orSchedule, outbreak, output, pack, pandemic, parking, paused, PDGFR, pirfenidone, powered, precisely, PRIME, pump, ratio, redefine, redundant, refine, reliance, remote, resting, rolling, Romilkimab, ROU, RV, scleroderma, seralutinib, sick, skip, spot, spread, SSc, stance, stay, STELLAR, stretching, strongly, Supreme, surging, survey, Talent, Talk, teleworking, temporarily, text, thing, thisReport, thousand, tired, TJCA, tocilizumab, town, transpire, transpired, triple, turnover, underwriter, underwritten, unethical, unrelated, Upgraded, vaccine, verify, video, virtual, virtually, wholly, workforce, workplace, worn, ZENITH

Removed: advisory, anterior, antisense, atrophy, attempt, attractive, bargaining, bear, Becker, BMD, budgeted, cachexia, calculate, capable, CDER, characteristic, children, CMT, collective, compute, concurrently, daily, dalantercept, disappointing, disuse, DMD, doubtful, Duchenne, dystrophy, elimination, encouraged, enroll, ESA, evaluable, experimental, facioscapulohumeral, fat, FDASIA, flexible, focal, follistatin, formulary, formulating, fraction, FSHD, gait, george, imaging, impacting, impede, implied, incident, indirect, inherited, intolerant, jean, John, Kumar, leg, listing, magnetic, median, medically, Milo, MRI, muscular, myalgia, myostatin, Nationwide, neurologic, neuromuscular, optimizing, Parent, pattern, Pharnext, pleotherapy, prioritized, profitably, Quisel, Ravindra, Regeneron, reserve, resonance, retaining, sarcopenia, scenario, serving, sIBM, simplify, sporadic, strategically, subsidiary, threatening, trevogrumab, tripping, underway, wasting, withdrawing, withhold


Name						State or other Jurisdiction of Incorporation or Organization
Acceleron Securities Corp.						Massachusetts
Acceleron Holding Ltd.						Bermuda
Acceleron Pharma Switzerland AG						Switzerland

Acceleron Pharma (XLRN) 10-K2020 FY Annual report

Content analysis